A structure-function study of ligand recognition by CD22beta.
B-cell-specific CD22 is a member of a group of cell adhesion molecules within the immunoglobulin superfamily that display binding to glycans with terminal sialic acid residues. Binding of endogenous ligands to CD22 triggers B-cell activation and proliferation. It is therefore conceivable that high affinity ligands for CD22 may be of value as inhibitors of B-cell activation in allergy and chronic inflammation. In this study, we aimed to delineate the structural requirements for ligand binding to CD22. A library of 20 mono-, di-, and trisaccharide analogs of the basic binding motif Neu5Ac(alpha2,6)Lac was synthesized and screened for affinity for CD22beta. In general, CD22 ligand recognition appeared to be rather tolerant with respect to structural modifications of the anomeric sugar on a mono-, di-, and trisaccharide level, although affinity was increased by the presence of a nitro aromatic group at C-2. The most potent monovalent ligand, Neu5Ac-4-nitrobenzoyl-Glc, was selected to generate multivalent ligands based on either a glutamate or Tris cluster core. All multivalent ligands displayed at least a 10-fold increased affinity for CD22 compared with the corresponding monovalent glycoside. Interestingly, a maximal gain in affinity was already obtained for bivalent ligands, regardless of the terminal glycoside. A trivalent Tris-based cluster of Neu5Ac-4-nitrobenzoyl-Glc displayed a 300-fold higher affinity compared with the basic binding motif, which makes it, to our knowledge, the most potent antagonist for CD22 yet synthesized. As our in vitro fluorescence-activated cell sorting studies demonstrated efficient cellular uptake of a CD22 substrate, the most potent ligand in this study may hold promise as a homing device for immunomodulatory compounds and cytostatics.
van Rossenberg
S M
SM
Leiden/Amsterdam Center for Drug Research, Division of Biopharmaceutics, Sylvius Laboratories, Leiden University, 2300 RA Leiden, The Netherlands. rossenbe@lacdr.leidenuniv.nl
Sliedregt
L A
LA
Autar
R
R
Piperi
C
C
Van Der Merwe
A P
AP
van Berkel
T J
TJ
Kuiper
J
J
Biessen
E A
EA
D000818:Animals; D015703:Antigens, CD / Q000737:chemistry* / Q000276:immunology / Q000378:metabolism*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000737:chemistry* / Q000276:immunology / Q000378:metabolism*; D001402:B-Lymphocytes / Q000276:immunology*; D001665:Binding Sites; D002240:Carbohydrate Sequence; D015815:Cell Adhesion Molecules; D002460:Cell Line; D004187:Disaccharides / Q000737:chemistry*; D004912:Erythrocytes / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry; D066298:In Vitro Techniques; D037102:Lectins; D008024:Ligands; D008213:Lymphocyte Activation; D051379:Mice; D008969:Molecular Sequence Data; D009005:Monosaccharides / Q000737:chemistry*; D011993:Recombinant Fusion Proteins / Q000737:chemistry; D051918:Sialic Acid Binding Ig-like Lectin 2; D013552:Swine; D014312:Trisaccharides / Q000737:chemistry*
D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; C497867:CD22 protein, human; C497868:Cd22 protein, mouse; D015815:Cell Adhesion Molecules; D004187:Disaccharides; D007074:Immunoglobulin G; D037102:Lectins; D008024:Ligands; D009005:Monosaccharides; D011993:Recombinant Fusion Proteins; D051918:Sialic Acid Binding Ig-like Lectin 2; D014312:Trisaccharides